Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Calabrò

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Journal of Clinical Medicine|October 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian CentrePasquale Fabio Calabrò, Letizia Biso, Marianna Lastella, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, George Wilding, Edwin Posadas, et al.
Cancers|September 17, 2020
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell CarcinomaIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo, et al.
Clinical Drug Investigation|June 6, 2026
Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in ItalyAndrea Marcellusi, Fabio Calabrò, Anna Maria Di Giacomo, et al.
Technology in Cancer Research & Treatment|February 24, 2025
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination ImmunotherapyRia Nagpal, Marina Campione, Sara Elena Rebuzzi, et al.
Journal of Clinical Medicine|September 28, 2024
Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant NivolumabRocco Simone Flammia, Gabriele Tuderti, Eugenio Bologna, et al.
Clinical Genitourinary Cancer|October 15, 2024
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI StudyAnnalisa Guida, Alessio Gili, Claudia Mosillo, et al.
European Urology Open Science|July 11, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint InhibitorsRoberto Iacovelli, Chiara Ciccarese, Daniela Arduini, et al.
Prostate Cancer and Prostatic Diseases|December 2, 2022
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohortMariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|October 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian CentrePasquale Fabio Calabrò, Letizia Biso, Marianna Lastella, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, George Wilding, Edwin Posadas, et al.
Cancers|September 17, 2020
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell CarcinomaIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo, et al.
Clinical Drug Investigation|June 6, 2026
Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in ItalyAndrea Marcellusi, Fabio Calabrò, Anna Maria Di Giacomo, et al.
Technology in Cancer Research & Treatment|February 24, 2025
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination ImmunotherapyRia Nagpal, Marina Campione, Sara Elena Rebuzzi, et al.
Journal of Clinical Medicine|September 28, 2024
Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant NivolumabRocco Simone Flammia, Gabriele Tuderti, Eugenio Bologna, et al.
Clinical Genitourinary Cancer|October 15, 2024
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI StudyAnnalisa Guida, Alessio Gili, Claudia Mosillo, et al.
European Urology Open Science|July 11, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint InhibitorsRoberto Iacovelli, Chiara Ciccarese, Daniela Arduini, et al.
Prostate Cancer and Prostatic Diseases|December 2, 2022
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohortMariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, et al.
Pageof 8